Medivir: Tibotec Files Application to Start a Phase I Clinical Trial for HCV Inhibitor

Medivir: Tibotec Files Application to Start a Phase I Clinical Trial for HCV Inhibitor

Business Wire - December 21, 2006

STOCKHOLM, Sweden -- Tibotec Pharmaceuticals Inc, on behalf of the Medivir (STO:MVIRB) and Tibotec collaborative drug discovery project on hepatitis C virus (HCV), has filed an application with a European regulatory authority to commence the first phase I clinical trial of an HCV NS3/4A protease inhibitor. This trial is estimated to begin during Q1/2007. The collaboration was initiated in November 2004. This milestone triggers a payment of EUR 2.5 million to Medivir.

"There is an important need for the development of innovative new drugs for hepatitis C. It is extremely pleasing that this project with joint resources and efforts now stands at the threshold of clinical trials. We look forward to 2007 and our continued collaboration with Tibotec" says Medivir's CEO Lars Adlersson.

Hepatitis C is a liver disease which is caused by infection with the hepatitis C virus (HCV). According to the WHO, 3% of the global population is infected with HCV, which means 200 million individuals. In the USA, 1.8% of the population is infected, that is 3.9 million people. In more than 60% of these cases, the HCV infection leads to chronic liver disease, cirrhosis and liver tumors. It is the most common reason for liver transplant. The HCV market is currently dominated by interferon-based treatments.

For more information about Medivir, please see the company's website, www.medivir.se

This information was brought to you by Waymaker http://www.waymaker.net

CONTACT: Medivir

Rein Piir, CFO and VP, IR

Tel: +46 8 5468 3123/ +46 708 537 292

SOURCE: Medivir
061221
BW061215

Copyright © 2006 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .